Impact of ERT and follow-up of 17 patients from the same family with a mild form of MPS II

Background: Mucopolysaccharidosis type II, also known as Hunter syndrome, is a rare X-linked recessive disorder caused by deficiency of the lysosomal enzyme Iduronate-2-Sulfatase (IDS), leading to progressive accumulation of Glycosaminoglycans (GAGs) in several organs. Over the years, Enzyme Replacement Therapy (ERT) has provided significant benefits for patients, retarding the natural progression of the disease. Results: The authors evaluated 17 patients from the same family with a mild form of MPS type II; the proband had developed acute decompensated heart failure refractory to clinical measurements at 23 years and needed a rather urgent heart transplant; however, he died from surgical complications shortly after the procedure. Nevertheless, subsequent to his tragic death, 16 affected male relatives were detected after biochemical tests identifying the low or absent activity of the IDS enzyme and confirmed by molecular analysis of the IDS gene. Following diagnosis, different options of treatment were chosen: 6 patients started ERT with Elaprase (R) (Idursulfase) soon after, while the other 10 remained without ERT. Eventually, 4 patients in the latter group began ERT with Hunterase (R) (Idursulfase Beta). None presented adverse effects to either form of the enzyme. Among the 6 individuals without any ERT, two died of natural causes, after reaching 70 years. Despite the variable phenotype within the same family (mainly heart dysfunctions and carpal tunnel syndrome), all 14 remaining patients were alive with an independent lifestyle. Conclusion: Here, the authors report the variable progress of the disease with and without ERT in a large Brazilian family with a slowly progressive form of MPS II, harboring the same missense variant in the IDS gene.

URI

https://observatorio.fm.usp.br/handle/OPI/49196

Referências

Adam MP, 1993, DIABETES MELLITUS 6Q
Chung YK, 2014, GLYCOCONJUGATE J, V31, P309, DOI 10.1007/s10719-014-9523-0
D'Avanzo F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041258
Grinberg H, 2012, CARDIOVASC PATHOL, V21, P358, DOI 10.1016/j.carpath.2011.10.004
Khan SA, 2018, MOL GENET METAB, V125, P44, DOI 10.1016/j.ymgme.2018.04.011
Kim C, 2017, J HUM GENET, V62, P167, DOI 10.1038/jhg.2016.133
Marler JA, 2005, AM J MED GENET A, V138A, P318, DOI 10.1002/ajmg.a.30970
Marler JA, 2010, AM J MED GENET C, V154C, P249, DOI 10.1002/ajmg.c.30262
Martin R, 2008, PEDIATRICS, V121, pE377, DOI 10.1542/peds.2007-1350
Muenzer J, 2011, GENET MED, V13, P95, DOI 10.1097/GIM.0b013e3181fea459
Muenzer J, 2009, PEDIATRICS, V124, pE1228, DOI 10.1542/peds.2008-0999
Ngu LH, 2017, MOL GENET METAB REP, V12, P28, DOI 10.1016/j.ymgmr.2017.05.002
omim, OMIM ONLINE MENDELIA
orpha, **DROPPED REF**
Parini R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082975
Quaio CRDC, 2012, JIMD REP, V4, P125, DOI 10.1007/8904_2011_90
Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
SASAKI CT, 1987, LARYNGOSCOPE, V97, P280
Semyachkina AN, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0807-x
Stapleton M, 2018, MOL GENET METAB, V125, P4, DOI 10.1016/j.ymgme.2018.01.003
Wraith JE, 2008, GENET MED, V10, P508, DOI [10.1097/GIM.0b013e31817701e6, 10.1097GIM.0b013e31817701e6]
Wraith JE, 2008, EUR J PEDIATR, V167, P267, DOI 10.1007/s00431-007-0635-4
Zarchi O, 2011, J PEDIATR-US, V158, P301, DOI 10.1016/j.jpeds.2010.07.056

Coleções

Artigos e Materiais de Revistas Científicas - FM/MFT
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/34
Artigos e Materiais de Revistas Científicas - LIM/36

Página do item completo